Clinical Trial Update: Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating orally administered AG-881 in patients with advanced solid tumors, including gliomas with IDH1 or IDH2 mutations; the trial status is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• AG-881 (vorasidenib)

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Glioma | Phase 1 | Status: COMPLETED